HWM
DNLI icon

Hemington Wealth Management’s Denali Therapeutics DNLI Stock Holding History

Hemington Wealth Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$0 Hold
34
– – ﹤0.01% 1580
2025
Q2 		$0 Buy
34
+18
+113% +$253 ﹤0.01% 1556
2025
Q1 		$0 Buy
16
+5
+45% +$96 ﹤0.01% 1558
2024
Q4 		$0 Buy
11
+8
+267% +$205 ﹤0.01% 1598
2024
Q3 		$0 Buy
+3
New +$74 ﹤0.01% 1542

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Hemington Wealth Management's DNLI Position: Q3 2025 in Review

Hemington Wealth Management held its Denali Therapeutics (DNLI) position steady in Q3 2025 at 34 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1580.

Hemington Wealth Management first reported a position in DNLI in Q3 2024 and has held it in 5 quarters since. 240 funds tracked by Wall St. Rank hold DNLI as of Q3 2025.

  • Hemington Wealth Management held 34 shares of Denali Therapeutics worth $0 as of Q3 2025.
  • Hemington Wealth Management left its Denali Therapeutics share count unchanged in Q3 2025.
  • Denali Therapeutics made up ﹤0.01% of Hemington Wealth Management's portfolio in Q3 2025, its #1580 holding.
  • Hemington Wealth Management first reported a position in Denali Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • 240 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2025.

Based on Hemington Wealth Management's 13F filing for Q3 2025, filed 24 Oct 2025.